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Abstract
Background: Squamous cell carcinoma (SCC) of the skin of the trunk and extremities may
present lymph node metastasis with difficult disease control and poor survival. The purpose of this
study was to identify risk factors for lymph node metastasis and outcome.
Patients/Methods: Retrospective review of 57 patients with locally advanced SCC of the trunk
and extremities was performed and several clinical variables including age, gender, ethnicity,
previously injured skin (burns, scars, ulcers and others), patient origin (rural or urban), anatomic
site and treatment were studied.
Results: Fifteen patients presented with previous skin lesions. Thirty-six were classified as T3
tumors and 21 as T4; 46 were N0, and 11, N1. Eleven N0 patients presented lymph node metastasis
during follow up. Univariate analysis identified previous skin lesions (ulcers and scars) as risk factor
for lymph node metastasis (p = 0.047). Better survival was demonstrated for T3 (p = 0.018)
classification. N0 patients who presented lymph node metastasis during follow up (submitted to
lymphadenectomy) had similar survival to patients without lymph node recurrence (p = 0.219).
Conclusion: Local advanced tumors are at risk of lymph node metastasis. Increased risk is
associated to previous lesions at tumor site. T4 classification have worse prognosis. Lymph node
recurrences in N0 patients, once treated, did not affect survival. For these patients, we propose
close follow up and prompt treatment of lymph node metastasis. These results do not support
indication for elective lymphadenectomy or sentinel node mapping. Further prospective studies
must address this issue.
Background
Squamous cell carcinoma of the skin (SCCS) is one of the
most common cancers around the word [1,2], with an
increasing incidence at a rapid rate among Caucasians in
Europe, America and Australia [3-6]. It affects typically
white skin populations and usually in body areas under
sun exposure. In majority of cases the progression is indo-
lent, and is easily cured by simple excision or radiother-
apy.
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Different from head and neck skin squamous cell carcino-
mas that present a higher incidence of lymph node
addressed by several studies [7-9], trunk and extremities
tumors usually do not present metastasis and the biologi-
cal behavior is less aggressive [10,11]. Although it may be
uncommon for a practicing dermatologist to observe a
metastasis, locally advanced tumors, more frequent
observed in referral hospitals, may present higher local
recurrence and tissue invasion, regional lymphatic and
even distant metastasis, consisting in a high risk group
[11,12]. Most of those cases have a late progress to lymph
node metastasis, with advanced local and regional dis-
ease. Nevertheless, at this point, disease control is difficult
and survival is poor [10-13].
The frequency of lymph node metastasis is debatable and
the reported rates vary considerable among investigators,
from 0.1 to 28%, with a resulting mortality from 50–75%.
Also, the inclusion of head and neck tumors in those
series is common [13,14]. Few studies have addressed spe-
cifically the SCCS of the trunk and extremities
[10,11,15,16]. Some have looked at several prognostic
factors, but most of them are heterogeneous or include
also initial stage lesions and head and neck tumors [10-
16].
The present study investigates a consecutive series of only
localized advanced SCCS of the trunk and extremities, in
order to define prognostic factors to lymph node metasta-
sis and survival.
Methods
Patients with locally advanced SCCS (T3 and T4 classifica-
tion – AJCC) [17]were identified from the Hospital do
Cancer de Barretos database – Barretos – Brazil. Patients
with tumors from head and neck or genital origin were
excluded. Patients with previous cancer diagnosis with
exception to cutaneous basal cell carcinoma were also
excluded due the difficulty to diagnosis the possible origin
of metastasis or death of cancer. A total of 57 consecutive
patients admitted and treated from October 1987 to
November 2005 were evaluated. Pathologic diagnosis of
SCC was confirmed in all cases. All of them were classified
according to the 2002 American Joint Committee on Can-
cer staging system and have T3 (tumor >5 cm) or T4 (inva-
sive of deep extra-dermal structures) classification.
Institutional Review Board approval was obtained and all
information retrospectively collected from medical
records.
Several clinical variables were examined. These include
age, gender, ethnicity, preceding chronic skin
lesions(burns, scars, varicosae ulcers and others) at the
site of the tumor, patient origin (rural or urban), anatomic
site and treatment. Patterns of lymph node metastasis,
recurrence and survival outcomes were also recorded.
We classified the patients related to lymph node metasta-
sis as: N0 – patients with no evidence of lymph node
metastasis at presentation; N0f – patients with no evi-
dence of lymph node metastasis at any time; N1 – patients
with lymph node metastasis at presentation; N1f –
patients with lymph node metastasis during follow up.
We considered lymph node metastasis at presentation
(N1) or during follow up (N1f) as endpoint. To analyze
the association between clinical variables and lymph
node metastasis the chi square, Fisher exact and T-test was
used. Overall survival (OS) was also studied, and curves
were constructed using the Kaplan-Meier method and
compared using the log-rank test. All tests were two-sided,
and a p-value of ≤ 0.05 was considered statistically signif-
icant.
Results
We included 57 patients in this study. They were 34 men
and 23 women; mean age was 61.9 years (range 30–91
years). 48 were Caucasians and 48 came from urban areas.
Preceding chronic skin lesions at the site of SCC occurred
in 15 cases. The tumors were sited at: the trunk, 14
patients; upper extremity (shoulder, arm and forearm), 7;
lower extremity (thigh and leg) 16; hand 12 and foot 8.
The T classification was T3 in 36 cases and T4 in 21 cases.
11 patients initially presented with lymph node metasta-
sis (N1).
Surgery was performed in 46 patients; exclusive radiation
therapy in 11. Eight patients received adjuvant radiation
therapy. Four of them on the area of lymph node metasta-
sis after lymphadenectomy, at discretion of the attending
physician. Major concerns were coalescent tumor and
more than 4 lymph node metastasis. Other 4 patients
received neoadjuvant radiation on the site of primary
tumor, with intention of local response and posterior
limb sparing surgery, what was possible in one patient.
Lymph node dissection was performed in 21 patients, 11
at the time of primary surgery and 10 during the follow up
period. No elective lymph node dissection or sentinel
node dissection was performed (Table 1). From 46
patients submitted to surgery, 38 had local control
(82.6%) and 8 (17.4%) local recurrence. From 11 patients
who received radiation therapy, 9 achieved local control.
Recurrence occurred in 2 (18.2%). There was no differ-
ence between the treatment modalities (p = 1.0).
From all patients, 22 presented nodal disease. 11 of them
presented lymph node metastasis at diagnosis (N1),
another 11 cases presented lymph node disease during
follow up (N1f) and the median time for it be diagnosedWorld Journal of Surgical Oncology 2008, 6:73 http://www.wjso.com/content/6/1/73
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was 11.5 months (ranging from 1.6 to 33.8 months). The
distribution of the lymph node metastasis in all cases is
presented in Table 1. 21 of those patients underwent
lymph node dissection, and 6 of them recurred at the
lymph node basin.
Of 11 patients who presented lymph node metastasis dur-
ing follow up, 7 (63.6%) were T3 and 4 (36.4%) were T4.
Nine were submitted to lymphadenectomy, 01 was
treated with radiotherapy and 01 refused treatment. The
treatment of choice of the primary tumor was radiother-
apy in 2 (18.2%). Five (45.5%) had surgery with local
reconstruction and 4 (36.4%) amputation. All patients
achieved local control of the primary tumor.
Considering the other recurrences, local ones occurred in
6 cases and 4 patients presented distant metastasis: one
patient had lung metastasis only, 2 had lung and bone
metastasis and the other one had disseminated metastatic
disease (lung, bone, liver and skin). The untreated patient
with lymph node metastasis had advanced local disease
and refused any treatment.
At the time of last follow up, 19 patients were alive with-
out evidence of disease, 17 died due to disease and 12
died from other causes. Nine patients were lost of follow
up. Actuarial 5-years overall survival was 40.6%.
The only statistically significant clinical variable associ-
ated to increased number of lymph node metastasis was
the presence of previous lesions on the skin. 9 of 22
patients with lymph node metastasis over the time pre-
sented previous lesions, versus 6 who did not (p = 0.047).
Lesions located in upper extremity presented more lymph
node metastasis, but did not reach statistical significance.
5 of 7 cases presented metastasis versus 17 of 50 from
other locations (p = 0.095). Regarding the N0 patients, 11
presented lymph node metastasis during the follow up
period (N1f) and again previous lesion was the only sta-
tistically significant factor: 5 of 11 patients with preceding
chronic skin lesion at the site of SCC presented lymph
node metastasis, versus 6 of 35 (p = 0.050). The mean
time of presentation of lymph node metastasis in the 11
N1f group was 12.7 months (median, 11.5 months). Yet,
the mean follow up of patients that never presented
lymph node metastasis over the time (N0f) was 30.6
months (median, 22.7 months) (Table 2).
Comparative survival curves demonstrate differences in
actuarial overall survival among patients with T3 and T4
classification (5 years overall survival 48.7% vs. 24.2%, p
= 0.018) (Figure 1). Among N0 and N1, there was differ-
ence, but it was not statistically significant (43.3% vs.
34.1%, p = 0.070) (Figure 2). The treatment of choice of
the primary tumor did not show differences in overall sur-
vival. Actuarial 5-years survival was 42.15% in the surgery
group versus 40.91% (p = 0,659) in the radiation group.
Overall survival estimative for N0 patients did not show
difference regarding the presentation of lymph node
metastasis over the time (N1f vs. N0f): (33.9% vs. 46.2%,
p = 0.948) (Figure 3) (Table 3). Despite the risk for devel-
opment of lymph node metastasis, comparative survival
did not show difference between patients with previous
skin lesions or not (37.7% vs. 42.2%, p = 0.507) (Figure
4).
Discussion
In our series of 57 locally advanced SCCS of the trunk and
extremities, we observed a high frequency of lymph node
metastasis. However, univariate analysis identified only
one significant risk factor for development of lymph node
metastasis, the presence of scar or ulcers previously in the
area of the tumor. This was observed also in other studies
[10,18]. The association of UV damage and a burn or
chronic wound may be associated to the aggressiveness
and metastasis in these patients. The anatomic site may be
a risk factor (upper extremity presented with more lymph
node metastasis), but the number of our cases was not
able to show statistical significance. Other studies
reported anatomic sites as high risk for metastasis, but
with conflicting results, and including head and neck
tumors [7,19,20].
The 24 cases of amputations (42.1%) also reflected the
selection of local advanced disease. Sixteen of 24 cases
(66.7%) were T4. Most of them had no possibility to try
other local treatment. Clinical difficulty to major recon-
Table 1: Treatment of 57 patients and characteristics of lymph 
node metastasis
Treatment Number %
Surgery
Wide local excision 1 1.8
Graft or flap 21 38.6
Amputation/desarticulation 24 42.1
Radiation therapy 11 19.3
Characteristics of lymph node metastasis
Anatomic site
Right axilla 4 7.0
Left axilla 7 12.3
Right inguinal groin 4 7.0
Left inguinal groin 7 12.3
None 35 61.4
Time of presentation
Initial (N1) 11 19.6
Recurrence (N1f) 11 19.6
None 35 60.8World Journal of Surgical Oncology 2008, 6:73 http://www.wjso.com/content/6/1/73
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struction was a concern in some cases, like diminished
vascular irrigation, old age, cardiovascular diseases or
other morbidities.
From our patients, 22 presented lymph node metastasis.
The high incidence of metastasis in this selected group,
confirms that tumors greater than 5 cm or invasive to soft
tissue or bones (T3 and T4) are high risk for lymphatic
spread. The 11 patients with metastasis at presentation,
also reflects possible referral bias to tertiary cancer center
and is similar to other reports [10,15]. Comparative sur-
vival demonstrates that more advanced tumors (T4) had
worse prognosis with poor outcome. This was expected
and confirms the value of T stage from the TNM classifica-
tion as a prognostic tool. The diagnosis of lymph node
metastasis during follow-up in N0 patients occurred in
24.4% of cases. This information would be enough for
indication of elective lymphadenectomy or sentinel node
dissection in most tumors. However, survival analysis
among patients without initial lymph node metastasis
(N0), showed no difference considering those who devel-
Overall survival for T3 and T4 patients Figure 1
Overall survival for T3 and T4 patients.
Table 2: Univariate analysis of risk factors for lymph node metastasis
Variable LN - (N0f) n (%) LN + (N1+N1f) n (%) p value
Age (mean) 64.22 58.38 0.154*
Gender 0.407¥
Male 19 (33.3) 15 (26.3)
Female 16 (28.1) 7 (12.3)
Ethnicity 0.514†
Caucasian 31 (54.4) 17 (29.8)
African 1 (1.7) 1 (1.7)
Residence 0.408¥
Urban 30 (52.6) 18 (31.6)
Rural 5 (8.8) 1 (1.7)
Lesion location 0.095¥
Upper extremity (without hand) 2 (3.5) 5 (8.8)
Trunk, hand and lower extremity 33 (57.9) 17 (29.9)
Previous lesion 0.047†
Present 6 (10.5) 09 (15.8)
Absent 29 (50.9) 13 (22.8)
Treatment modality 0.309¥
Surgery 27 (47.4) 19 (33.3)
Radiation therapy 8 (14.0) 3 (5.3)
T stage 0.158¥
T3 25 (43.8) 11 (19.3)
T4 10 (17.5) 11 (19.3)
* T – test
† Chi square
¥ Fisher exactWorld Journal of Surgical Oncology 2008, 6:73 http://www.wjso.com/content/6/1/73
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oped lymph node metastasis during the follow up or not
(N0f versus N1f). One comment is that all the patients
were closely followed, and lymph node disease was
treated by lymph node dissection soon after diagnosis. So,
similar survival might be explained by the prompt ther-
apy. It is important to advert this was a retrospective study
with a relatively small sample with heterogeneous treat-
ment options, submitted to Univariate analyze. The
results show no indication for elective lymph node dissec-
tion, or sentinel node mapping in these specific setting of
patients, since careful surveillance and early surgery after
clinical/radiological diagnosis is performed, but this affir-
mation needs confirmation in prospectively randomized
studies. Distant metastasis is not usual even in locally
advanced or after lymph node metastasis in SCCS of the
trunk and extremities. Only 4 patients had metastasis in
distant organs. Despite of this, approximately 1/3 of
patients died of disease, mainly due to loco-regional fail-
ure, which is the major problem in control disease of
these patients.
Conclusion
Local advanced tumors are at risk of lymph node metasta-
sis. Increased risk is associated to previous lesions at
tumor site, and T4 classification tumors have worse prog-
nosis. Lymph node recurrences in N0 patients, once
treated, did not affect survival. For these patients, we pro-
pose close follow up and prompt treatment of lymph
Table 3: Overall survival of 57 patients with advanced SCCS 
according to clinical variables
Groups N 5-years survival (%) p value
T stage 0.018
T3 36 48.7
T4 21 24.2
N stage 0.070
N0 46 43.3
N1 11 34.1
Anatomic site 0.378
Upper extremity 07 47.6
Other 50 40.0
Previous lesion 0.507
Present 15 37.7
Absent 42 42.2
Lymph node metastasis 0.948
Present (N1f) 11 33.9
Absent (N0f) 35 46.2
Overall survival for N0 patients considering presence of  lymph node metastasis during follow-up Figure 3
Overall survival for N0 patients considering presence 
of lymph node metastasis during follow-up.
Overall survival for N0 and N1 patients Figure 2
Overall survival for N0 and N1 patients.
Overall survival considering the presence of previous skin  lesions Figure 4
Overall survival considering the presence of previous 
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node metastasis. These results do not support indication
for elective lymphadenectomy or sentinel node mapping.
Further prospective studies must address this issue.
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